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Abstract 
Background: Age has been reported as an independent prognostic factor for melanoma-specific survival (MSS). We 
tested the hypothesis that age impacts the host anti-tumor immune response, accounting for age-specific survival 
outcomes in three unique melanoma patient cohorts.
Methods: We queried the U.S. population-based Surveillance, Epidemiology, and End Results Program (SEER), the 
prospective tertiary care hospital-based Interdisciplinary Melanoma Cooperative Group (IMCG) biorepository, and 
the Cancer Genome Atlas (TCGA) biospecimen database to test the association of patient age at time of melanoma 
diagnosis with clinicopathologic features and survival outcomes. Age groups were defined as ≤45 (young), 46–65 
(intermediate), and >65 (older). Each age group in the IMCG and TCGA cohorts was stratified by tumor infiltrating lym-
phocyte (TIL) measurements and tested for association with MSS. Differential expression of 594 immunoregulatory 
genes was assessed in a subset of primary melanomas in the IMCG and TCGA cohorts using an integrative pathway 
analysis.
Results: We analyzed 304, 476 (SEER), 1241 (IMCG), and 292 (TCGA) patients. Increasing age at melanoma diagnosis 
in both the SEER and IMCG cohorts demonstrated a positive correlation with tumor thickness, ulceration, stage, and 
mortality, however age in the TCGA cohort did not correlate with mortality. Older age was associated with shorter 
MSS in all three cohorts. When the young age group in both the IMCG and TCGA cohorts was stratified by TIL status, 
there were no differences in MSS. However, older IMCG patients with brisk TILs and intermediate aged TCGA patients 
with high lymphocyte scores (3–6) had improved MSS. Gene expression analysis revealed top pathways (T cell traffick-
ing, communication, and differentiation) and top upstream regulators (CD3, CD28, IFNG, and STAT3) that significantly 
changed with age in 84 IMCG and 43 TCGA primary melanomas.
Conclusions: Older age at time of melanoma diagnosis is associated with shorter MSS, however age’s association 
with clinicopathologic features is dependent upon specific characteristics of the study population. TIL as a read-out 
of the host immune response may have greater prognostic impact in patients older than age 45. Recognition of age-
related factors negatively impacting host immune responses may provide new insights into therapeutic strategies for 
the elderly.
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Background
Age is an important prognostic factor in cutaneous mela-
noma, which commonly arises in the elderly [1–3]. The 
median age at initial melanoma diagnosis is 63 and the 
highest percentage of melanoma-related deaths occur in 
patients aged 75–84 [4]. Differences in the natural history 
of melanoma between younger and older patients have 
been attributed to reduction in naïve T cells, decreased T 
cell functionality due to loss of co-stimulatory molecules, 
T cell exhaustion, and reduction in pro-inflammatory 
cytokine secretion [5, 6]. Tumor infiltrating lympho-
cytes (TIL) are believed to be a partial surrogate marker 
of the host anti-tumor immune response and are also 
thought to confer prognostic significance in melanoma. 
However, immunologic metrics have yet to be included 
in the melanoma American Joint Committee on Cancer 
(AJCC) staging system [7–11]. It is unclear whether age’s 
impact on the host immune response is reflected by TIL 
measurements.
There are several unanswered questions regarding the 
impact of age on melanoma prognosis. It is unknown 
whether melanomas of the elderly embody a distinct 
clinical and biologic entity compared to melanomas 
in younger patients [12]. Understanding the interplay 
between age, the host immune response, and the tumor 
immune microenvironment is especially critical as mela-
noma is increasing in incidence and U.S. demographics 
are shifting to a larger aging population. Therefore, the 
diagnosis and treatment of melanoma patients, particu-
larly at advanced ages and stages, represent both a public 
health issue and an economic burden [13, 14].
The primary objective of this study is to analyze and 
dissect the impact of age at time of melanoma diagnosis 
on clinicopathologic features, the anti-tumor immune 
response as measured by TILs, and melanoma-specific 
survival (MSS) by examining three unique melanoma 
patient cohorts: the U.S. Surveillance, Epidemiology, 
and End Results Program (SEER), New York University’s 
(NYU) Interdisciplinary Melanoma Cooperative Group 
(IMCG) biorepository database, and the Cancer Genome 
Atlas (TCGA) biospecimen database. Secondly, we aim 
to identify the functional impact of aging on the host 
immune response by analyzing differential expression of 
immunoregulatory genes with aging in the IMCG and 
TCGA cohorts.
The rationale for analyzing three distinct cohorts is to 
identify whether conclusions drawn from smaller, more 
specific patient cohorts like IMCG and TCGA can be 
extrapolated as representative of the general population, 
as embodied by SEER. This exploration is particularly 
crucial given the unique features provided by the IMCG 
and TCGA databases that are not included in the SEER 
database such as TIL status, genetic sequencing, and 
gene expression data. Several publications analyze SEER 
for melanoma-specific outcomes related to age [3, 15–17] 
however these studies focus only on limited time frames 
rather than on the entirety of available SEER data as we 
provide here. To our knowledge, no studies currently 
approach age from the angle of a multi-cohort perspec-
tive. Clinical and research assumptions are commonly 
based on data from these cohorts, although newer data-
bases like TCGA contain a wealth of genomic informa-
tion not yet tested against existing population-based 
data (SEER) or tertiary care hospital-based (IMCG) data. 
Understanding how to contextualize data on both aging 
and the immune response from each cohort is critically 





SEER is a U.S. population-based, publicly-available 
database sponsored by the National Cancer Institute 
(NCI) that records cancer statistics among specific 
demographic registries representing 28  % of the U.S. 
population. We queried the SEER database for stage I–
IV melanoma patients diagnosed from 1973 to 2012. 
SEER*Stat Version 8.2.1 (NCI, Bethesda, MD) was used 
to identify all patients diagnosed with invasive melanoma 
based on the International Classification of Diseases for 
Oncology, Third Edition melanoma codes (M8720-8790). 
Available patient information includes age, gender, year 
of diagnosis, race, survival in months, and vital status. 
Available pathologic information includes primary mela-
noma site, thickness, presence of ulceration or mitoses, 
and stage at diagnosis, but not TIL status [18, 19]. There 
is no gene expression data available for the SEER cohort.
IMCG
The IMCG database is a tertiary care hospital-based mel-
anoma biorepository at NYU Langone Medical Center. 
The IMCG protocol is approved by NYU’s institutional 
review board and authorizes research use of patient 
tumor biospecimens and blood samples and requires 
prospective recording of all demographic, clinical, and 
pathologic patient information, with comprehensive, pro-
tocol-driven follow-up. We queried the IMCG database 
to identify patients with primary cutaneous melanoma 
who presented to NYU from 2002 to 2013. Informed 
consent for use of clinical data and tissue was obtained 
from all patients at the time of study enrollment.
Standard histopathologic features for all primary mela-
noma cases were reviewed and determined by the IMCG 
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pathologist including primary tumor thickness, ulcera-
tion, mitoses, and histologic subtype. TILs are graded 
as brisk (present throughout the vertical growth phase 
(VGP) or infiltrating the entire base of the VGP), non-
brisk (present in one or more foci of the VGP), or absent 
(no lymphocytes are in contact with the VGP but may be 
present in perivascular or fibrotic areas) [20].
TCGA
TCGA is a collaborative effort run through the NCI and 
National Human Genome Research Institute (NHGRI) 
that conducts genomic analyses on human tumors to 
understand the molecular basis of cancer [21]. Patients 
who underwent surgical resection of a primary or met-
astatic melanoma were consented for the study if the 
biospecimen had at least 60 % tumor nuclei present and 
enough volume of material available to undergo all plat-
forms of genomic analysis, as well as availability of ger-
mline DNA. Patients were excluded if they received 
radiation therapy to the site of the biospecimen or 
received prior systemic therapy, with the exception of 
adjuvant interferon alfa administered at least 90  days 
prior to obtaining the tissue sample [21, 22].
TCGA records clinicopathologic information includ-
ing age, gender, race, primary tumor thickness, ulcera-
tion, mitoses, histologic subtype, stage at diagnoses, and 
survival outcomes [22]. TILs were measured in primary 
and metastatic melanoma tissues as a lymphocyte score 
(LScore), defined as the sum of lymphocyte distribution 
(0–3) and lymphocyte density (0–3). Lymphocyte dis-
tribution was graded as: no lymphocytes present in the 
tumor tissue (0) and lymphocytes present in less than 
25  % (1), 25–50  % (2), and greater than 50  % (3) of the 
tumor tissue. Lymphocyte density was graded as absent 
(0), mild (1), moderate (2), and severe (3) [22]. Based on 
this sum, LScores of 0 or 2–6 are possible.
Immunoregulatory gene expression analysis
Using the IMCG biorepository, RNA was isolated from 
macrodissection of 84 formalin-fixed paraffin embed-
ded (FFPE) primary melanoma sections using the Rneasy 
FFPE Kit (Qiagen, Valencia, CA) per manufacturer pro-
tocol [23] and was subjected to quality control measures. 
Nanostring gene expression analysis was conducted per 
manufacturer protocol using the NCounter® GX Human 
Immunology Kit (Nanostring Technologies, Seattle, WA, 
USA), comprised of 594 immunoregulatory genes [24]. 
RNA sequencing data for 43 primary melanomas previ-
ously published by the TCGA [22] (level 3 normalized 
data) was also analyzed for the same immunoregulatory 
genes and for validation of the IMCG gene expression 
analysis.
Statistical analysis
Patient age at time of initial melanoma diagnosis was 
classified as: young (≤45), intermediate (46–65), and 
older (>65), although no human data has clearly identi-
fied age categories that define immune system quality.
Baseline patient characteristics in each cohort were 
compared within each age category using the Chi square 
test. Baseline characteristics in each cohort were also 
tested for overall association with age and TIL measure-
ments (IMCG and TCGA only). Kaplan–Meier curves 
were generated and compared by the log-rank test to esti-
mate MSS distribution for each age group in each cohort 
and for TIL status in the IMCG and TCGA cohorts. MSS 
was calculated as time from initial melanoma diagnosis 
to time of death due to melanoma. Patients who were 
alive or died due to other reasons were censored, and 
their MSS was calculated as time from initial melanoma 
diagnosis to last follow-up time. For this analysis in the 
TCGA cohort specifically, MSS was calculated as time 
from TCGA specimen sampling to the time of death due 
to melanoma or last follow-up time. Multivariate cox 
regression models were used to calculate adjusted hazard 
ratios (HR) and 95  % confidence intervals (CI) of older 
age groups for MSS for each cohort. Multivariate analy-
sis for MSS included gender and melanoma stage at diag-
nosis and age groups as categorical variables, which are 
coded as two dummy variables representing intermediate 
and older age. Pooled HR was calculated using a fixed-
effects model to evaluate the relationship between age 
categories and MSS [25].
IMCG and TCGA gene expression data were compared 
amongst the three age groups by analysis of variance 
(ANOVA). False discovery rate (FDR) was estimated by 
the Benjamin Hochberg approach to account for multiple 
testing correction. All analyses were performed with R 
version 3.1.1. Ingenuity pathway analysis (IPA) software 
(Qiagen, Redwood City, CA, USA) was used to identify 
immunologic pathways that change most with aging [26]. 
The core analysis function was used to determine the top 
pathways, upstream regulators, and regulatory effects 
associated with aging in IMCG and TCGA primary 
melanomas.
Results
Older age in SEER is associated with male gender and more 
advanced melanoma stage
We examined the relationship of age at melanoma diag-
nosis with patient and tumor characteristics in the SEER 
database. The age distribution of 304,476 melanoma 
patients from SEER registries from 1973 to 2012 is: ≤45 
(n = 72,976, 24 %), 46–65 (n = 117,158, 38 %), and >65 
(n = 114,342, 38 %) (Table 1). Male gender predominates 
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in the intermediate (59  %) and older age (64  %) groups 
compared to the young age group in which there are 
more females (58 %) (p < 0.001).
Rates of regional and distant disease extent, and thus 
stage, rise with aging while localized disease, particu-
larly stage I melanoma, is more common in the younger 
age groups (p < 0.001). Thicker melanomas staged as T3 
(2.01–4  mm) and T4 (>4  mm) are more common with 
aging, with T4 occurring in 4 % of young vs. 9 % of older 
patients (p < 0.001). Ulceration is also more common in 
the older age group (17 %) compared to the young (8 %) 
and intermediate (11 %) age groups (p < 0.001). Overall, 
male gender and thicker, more ulcerated primary mela-
nomas, translating to more advanced stage at diagnosis, 
positively correlate with older age older at time of mela-
noma diagnosis in SEER patients (Additional file 1: Table 
S1A).
IMCG replicates all SEER data and is representative of the 
general population
We examined the relationship of age at melanoma diag-
nosis with patient and tumor characteristics in the IMCG 
database and compared this to the SEER data. The age 
distribution of 1241 melanoma patients in the IMCG 
cohort from 2002 to 2013 is: ≤45 (n = 308, 25 %), 46–65 
(n = 439, 35 %), and >65 (n = 494, 40 %) (Table 1). Simi-
lar to the SEER cohort, more males comprise the inter-
mediate (58  %) and older (60  %) age groups, while the 
young age group has more females (56 %) (p < 0.001).
Stage I melanoma diagnoses are more common in 
the young (82  %) and intermediate (78  %) compared to 
the older age group (66 %) (p < 0.001). Similar to SEER, 
aging is also associated with thicker melanomas. T1 
(<1.01  mm) is most common in young (68  %) patients 
(p < 0.001), whereas T4 is most common in older (12 %) 
patients (p < 0.001).
Unfavorable prognostic factors such as ulceration 
occur in only 12 % of the young compared to 24 % of the 
older age group (p < 0.001). Nodular melanomas (NM), 
thought to represent a more aggressive histologic sub-
type than superficial spreading melanoma (SSM), occur 
in 27 % of the older compared to only 15 % of the younger 
age group (p < 0.001). TIL grade is not significantly asso-
ciated with age (p = 0.166) (Additional file 1: Table S1B). 
Overall, IMCG replicates SEER population-based data, 
suggesting that extrapolations made from the IMCG 
database are applicable to the general population.
Age in TCGA carries less association with aggressive 
clinicopathologic features compared to SEER and IMCG
We examined the relationship of age at time of speci-
men acquisition with patient and tumor characteristics 
in TCGA and compared this to the SEER and IMCG 
analyses. The age distribution of 292 melanoma patients 
in TCGA is: ≤45 (n = 71, 24 %), 46–65 (n = 128, 44 %), 
and >65 (n =  93, 32  %) (Table  1). Compared to IMCG 
which focuses on primary melanomas, the TCGA cohort 
included only 41 primary melanomas and a majority of 
melanoma metastases (160 regional lymph nodes, 52 
regional skin or soft tissue metastases, and 35 distant 
metastases). Mean tumor thickness for the TCGA pri-
mary melanomas TCGA was 4.9  mm [22] compared to 
1.65 mm in IMCG. Unlike SEER and IMCG, there were 
no significant differences in gender among the age groups 
in TCGA (p = 0.56).
Primary tumor thickness and staging trends by age in 
TCGA were reflective of SEER and IMCG results. Young 
TCGA patients were more commonly diagnosed with 
stage I melanoma (36 %) compared to the older age group 
(13  %), while T4 melanomas occurred more in older 
(44 %) versus younger (21 %) patients (p < 0.001). Ulcera-
tion status does not differ by age (p = 0.37). Overall, the 
only clinicopathologic features that significantly associ-
ated with aging in the TCGA cohort were increasing pri-
mary tumor thickness (p = 0.003) and stage (p < 0.001). 
LScore did not significantly associate with age (p = 0.16) 
(Additional file 1: Table S1C).
Older age predicts worse MSS in all three cohorts
Median follow-up time was 6.25, 4.04, and 3.62 years for 
SEER, IMCG, and TCGA, respectively. Melanoma-spe-
cific mortality rates increase with advancing age at time 
of melanoma diagnosis in SEER and IMCG (p  <  0.001), 
however there are no significant differences in mela-
noma-specific mortality rates by age at specimen acquisi-
tion in TCGA (p = 0.37) (Table 1) This data is impacted 
by the varying definitions of age and characteristics 
required for patient eligibility in each cohort. However, 
older age predicts worse MSS in all three cohorts (Fig. 1) 
(SEER p < 0.001, IMCG p = 0.001, TCGA p < 0.001 by 
log rank test).
Aging corresponds with shorter MSS in each cohort 
in multivariate analysis, most prominently in SEER and 
IMCG, independent of gender or stage at diagnosis. 
Adjusted HRs for MSS in the intermediate compared to 
the young age group were 1.42 in SEER (95 % CI 1.32–
1.54), 2.50 in IMCG (95  % CI 1.01–6.19), and 1.47 in 
TCGA (95  % CI 0.85–2.53) (Fig.  2). Adjusted HRs for 
MSS were even higher for older patients in compari-
son to the young patient reference group: 2.19 in SEER 
(95  % CI 2.03–2.36), 5.25 in IMCG (95  % CI 2.20–
12.55), and 1.73 in TCGA (95 % CI 0.99–3.01) (Fig. 2). 
Meta-analysis confirms that overall risk of melanoma-
specific death is highest in patients older than 65 at 
time of melanoma diagnosis (adjusted HR 2.19, 95 % CI 
2.03–2.36) (Fig. 2).
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TIL intensity positively correlates with MSS in IMCG 
and TCGA
We examined the prognostic impact of TIL grading sys-
tems in IMCG and TCGA. In the IMCG cohort, reflec-
tive of the SEER population-based data, TIL status 
derived from primary melanomas was graded as: absent 
(n  =  388, 31  %), non-brisk (n  =  330, 27  %), and brisk 
(n  =  523, 42  %) (Fig.  3). Brisk TILs, theoretically rep-
resentative of a more robust host anti-tumor immune 
response, predominate in the young (66 %) and interme-
diate (64 %) age groups compared to older patients (56 %) 
(p  =  0.04). Conversely, the percentage of patients with 
non-brisk TILs increases from young (34 %) to interme-
diate (36 %) to older (44 %) age group (p = 0.04). IMCG 
patients with brisk TIL grade had improved MSS com-
pared to patients with non-brisk and absent TIL grades 
(p = 0.001).
In TCGA, TILs were scored in both primary and 
metastatic melanoma tissues: LScore 0 (n  =  91, 27  %), 
2 (n = 77, 23 %), and 3–6 (n = 163, n = 50 %) (Fig. 3). 
MSS curves for LScores 3, 4, 5, and 6 clustered together 
and were therefore grouped. The trend in distribution 
of LScores amongst TCGA melanomas is very similar 
to that of TIL grades in IMCG melanomas, despite the 
differences in tissue sources and age definitions for each 
cohort. There were no differences in lymphocyte dis-
tribution (p  =  0.251) lymphocyte density (p  =  0.125), 
or LScores (p = 0.269) amongst the three age groups in 
TCGA. The percentage of TCGA patients with LScore 0, 
potentially suggestive of a weaker host immune response, 
was not significantly different among the young (21  %), 
intermediate (31 %), or older (29 %) age groups. However, 
across all age groups, TCGA patients with higher LScores 
(3–6) had improved MSS compared to patients with 
Fig. 1 Older age predicts worse melanoma-specific survival in each melanoma cohort
Fig. 2 Multivariate analysis and meta-analysis summary demonstrate shorter melanoma-specific survival in middle aged (46–65) and older (>65) 
patients compared to patients age 45 or less at time of melanoma diagnosis, independent of melanoma stage or gender
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lower LScores (0 or 2) (p  =  0.005) (Fig.  3). Analysis of 
the IMCG and TCGA cohorts shows that increased TIL 
intensity, independent of melanoma cohort, TIL grading 
system, or tissue type positively correlates with MSS.
TILs may have greater prognostic value in patients older 
than age 45
Given that the highest TIL measures (brisk TIL grade 
and LScore 3–6) are associated with prolonged MSS, we 
investigated whether the association of robust TILs with 
MSS persists when TIL status is examined in the context 
of each individual age group. In IMCG patients, there 
were no differences in MSS when the young (p = 0.1) or 
intermediate (p = 0.5) age groups were stratified by TIL 
grade. However, IMCG patients in the older age group 
with brisk TILs had improved MSS compared to older 
patients with non-brisk and absent TILs (p  =  0.008) 
(Fig.  4). In TCGA, LScore stratification in the young 
(p  =  0.155) or older (p  =  0.774) age groups did not 
impact MSS. However, a high LScore (3–6) conferred 
improved MSS in intermediate aged patients compared 
to LScore ≤2 (p = 0.005) (Fig. 4). These findings suggest 
that TIL grading may have greater prognostic impact in 
patients older than age 45.
Differential gene expression analysis demonstrates 
decreased immune cell trafficking in older patients
Differential immunoregulatory gene expression was ana-
lyzed among the 3 age groups in IMCG (n  =  84) and 
TCGA (n =  43) primary melanomas. Clinicopathologic 
Fig. 3 Tumor infiltrating lymphocyte distribution is a comparable between the IMCG and TCGA cohorts and b is prognostic for melanoma-specific 
survival
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characteristics of these melanomas are documented in 
Additional file 2: Table S2. The most significant differen-
tially expressed genes (p < 0.05) among the young, inter-
mediate, and older age groups are reported for the IMCG 
and TCGA in Additional file 3: Table S3A and B, respec-
tively. IL13RA1 was the only gene found in both cohorts 
in this analysis and showed significantly decreased 
expression with aging.
The top canonical pathways significantly implicated 
with aging and shared between the cohorts included: (1) 
crosstalk between dendritic cell and natural killer cells, 
(2) granulocyte adhesion and diapedesis, (3) T helper 
cell differentiation, and (4) IL-10 signaling. Additionally, 
ICOS signaling, CD28 signaling, and role of NFAT in the 
immune response were also top altered pathways in the 
IMCG with aging, as was HMGB1 signaling in the TCGA 
cohort.
Predicted upstream regulators common to both 
cohorts included CD3, CD28, IFNG, and STAT3. In both 
the IMCG and TCGA cohorts, there was also diminished 
cellular function including decreased immune cell traf-
ficking and impaired T cell development.
Discussion
Our aging analysis of three melanoma cohorts demon-
strates with collective agreement that age is an inde-
pendent prognostic factor for MSS, consistent with 
several other studies [1, 3, 27]. However, there are 
inherent differences among the three examined patient 
populations and we emphasize that drawing broad con-
clusions from analysis of any one group may be mislead-
ing. SEER follows over 300,000 U.S. melanoma patients 
representative of the general population and is a gold 
standard from which reliable deductions regarding 
melanoma demographics, clinicopathologic features, 
and outcome measures can be made. Our SEER analy-
sis shows that with increasing age, primary melano-
mas exhibit increased thickness and more unfavorable 
pathologic features, leading to more advanced stages, 
increased mortality, and worse MSS, independent of 
Fig. 4 Measures of tumor infiltrating lymphocytes in the a IMCG and b TCGA cohorts may have more prognostic impact in patients older than 
45 years of age
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gender and stage at diagnosis. This validates an analysis 
of 13,581 patients in the AJCC melanoma database in 
which age was the third most significant prognostic fac-
tor for localized melanomas after thickness and ulcera-
tion [28–30].
IMCG data identically replicate the benchmark results 
established by SEER. Therefore, extrapolation of results 
from our hospital-based IMCG cohort is valid and appli-
cable to the general population that SEER represents, 
despite the possible referral bias that may be intrinsic 
to a large, academic, tertiary care medical center. Con-
versely, the TCGA population is distinct in several ways 
from SEER and IMCG. TCGA consists of highly pre-
selected patients and requires sufficient tissue quantity 
for genomic studies. Therefore, TCGA is mostly com-
prised of metastases [22] and the selected primary mel-
anomas are naturally thicker than average. This bias is 
important in our analysis if we assume that metastatic 
melanomas differ biologically and immunologically from 
primary melanomas. Additionally, the age at time of 
TCGA specimen acquisition often does not match the 
definition of age at time of primary diagnosis as defined 
in SEER and IMCG. TCGA sample size is also only 25 % 
that of the IMCG. These differences aid in explaining why 
the TCGA age analysis shows no association with gender, 
ulceration, or mortality rates, unlike SEER and IMCG. 
The TCGA clearly remains a valuable resource, but inter-
pretation of TCGA data should be applied in the context 
of that cohort’s specific patient population rather than 
broadly generalized.
Confounding factors not specifically studied in this 
investigation should be emphasized as potentially con-
tributing to the worse outcomes seen in elderly patients. 
Physician bias may occur in which elderly patients are 
offered less strict clinical surveillance or fewer oppor-
tunities for adjuvant therapies. Elderly patients are also 
less frequently offered SLN biopsies, resulting in a per-
centage of clinically node negative but pathologically 
node positive patients, and thus current staging data by 
age may be underestimated [31]. Additionally, oncolo-
gists may hesitate to offer aggressive systemic therapy 
for advanced melanoma in the elderly [12, 32]. Most 
immunotherapy clinical trials in melanoma do not pro-
spectively stratify patients by age to assess for differences 
in outcome, but the few that do show that response to 
immunotherapy is independent of age. This suggests that 
age should not be a critical factor in determining patient 
candidacy for immunotherapies [33–36]. Socioeco-
nomic factors also impact access to health care. Elderly 
patients may be less able to seek out medical care due to 
declining functional status, financial considerations, or 
decreased social support and isolation. Finally, it should 
be acknowledged that other chronic inflammatory medi-
cal conditions and certain viral infections may also cor-
relate with age and could potentially confound our 
observations. However, this information is not recorded 
in any of our database cohorts and thus requires a sepa-
rate analysis.
Melanoma’s escape from an aging, dampened host 
immune surveillance mechanism is one factor hypoth-
esized to account for decreased MSS in the elderly [6]. 
This may explain why brisk TIL grade has been proposed 
to be more common in younger rather than older patients 
[8]. However, in our datasets, lymphocytic markers did 
not directly correlate with age on the whole. Although 
TIL grading is an imperfect tool in gauging host immune 
function, it is a readily accessible measurement and com-
monly recorded in melanoma pathology reports, despite 
lack of consistent clarity on its prognostic impact [9, 11, 
20, 37]. In this case, it is possible that use of different age 
cut-offs may have yielded a significant correlation with 
TIL groups. Furthermore, the presence of TILs histologi-
cally does not necessarily translate into the appropriate 
functionality. Comparing two different TIL grading sys-
tems may also pose a barrier in standardizing our data. 
TIL grade has been previously studied in primary mela-
nomas and while a potentially subjective measure, has 
shown high interobserver agreement [10]. Conversely, 
TCGA LScore has not previously been validated and is 
employed in a heterogeneous group of tissues consisting 
of fewer primaries and a majority of metastases. Despite 
these differences, a high degree of lymphocytic infiltra-
tion represented by both brisk TIL grade and LScore 3–6 
correlates with improved MSS. In selected patient groups 
over age 45, the highest TIL measures did correlate with 
MSS, whereas in the young groups, there were no sig-
nificant differences in TIL measures with survival. While 
TILs represent a semi-quantitative measure of lympho-
cytes, improved markers of the overall tumor immune 
microenvironment may be even more useful.
Despite limitations in comparing TIL grade and LScore, 
the proportions of each TIL grade to the corresponding 
LScore (brisk TILs/LScore 3–6, non-brisk TILs/LScore 
2, absent TILs/LScore 0) are strikingly similar. Further-
more, TCGA MSS curves for LScore 0 and 2 overlap 
until 60  months’ follow-up, mirroring the overlapping 
IMCG MSS curves for non-brisk and absent TIL grades. 
The consistent survival distinction between strong lym-
phocytic infiltrates, represented by brisk TILs/LScore 
3–6, and the less intense infiltrates suggests a prognostic 
cut-off point. TIL classification in young patients did not 
impact MSS in IMCG or TCGA, which may be partially 
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explained by small sample size of TCGA or because TIL 
presence tends to have a higher incidence in thin mela-
nomas [7, 38], which are more common in IMCG. Our 
data highlights that presence of an intense immune infil-
trate may carry more prognostic weight in older patient 
populations, in which more variable levels of or decline 
in immune function exist. In younger patients (≤45), 
immune function is more universally intact. Factors other 
than host anti-tumor immunity may contribute more 
significantly to prognosis, such as underlying molecular 
drivers.
To better define the immunologic mechanisms under-
lying age’s impact on decreased MSS, we analyzed gene 
expression signatures of primary melanomas stratified by 
age. Aging was associated with decreased T cell differ-
entiation, activation and migration. The differential gene 
expression by age was driven by upstream regulators 
common to each cohort such as CD3, a component of the 
mature T cell receptor, and CD28, a co-stimulatory mol-
ecule. In the IMCG cohort for example, CD28 and CD3 
with aging decreased expression of GZMA and GZMB, 
proteases important in T cell and NK-cell-mediated 
tumor cell lysis. Overall, with aging there is evidence of 
a depressed anti-tumor immune response due to T cell 
dysfunction.
Conclusion
In summary, we demonstrate through analysis of three 
distinct melanoma patient cohorts that age at time of 
melanoma diagnosis is a clear prognostic indicator pre-
dicting MSS. SEER and IMCG demonstrate that older 
age at melanoma diagnosis associates with male gender, 
advanced stage, and more adverse clinicopathologic fea-
tures including presence of ulceration, mitoses, and more 
high-risk histologic subtypes. In contrast, the TCGA 
cohort is representative of mostly advanced stage patients 
with thicker melanomas and thus age at time of speci-
men sampling does not factor into prognosis as signifi-
cantly. Our study uniquely highlights the similarities and 
differences of each melanoma cohort on which multiple 
conclusions regarding prognosis are based. Clinicians 
should utilize an appropriate melanoma cohort that is 
specific to their patient population to accurately estimate 
patient prognosis and to judge age’s impact on the host 
immune response. Interestingly, TIL status as a meas-
ure of the host anti-tumor immune response appears to 
influence prognosis most in patients older than 45. As 
TILs are increasingly being considered as an informative 
prognostic marker, incorporation of age and TIL status 
as joint prognostic markers may strengthen their value in 
projecting outcomes compared to either variable alone. 
Finally, gene expression analysis of each age group has 
revealed alterations in key regulators of the host immune 
response with aging. Recognition of age-related fac-
tors negatively impacting host immune responses may 
provide new insights into therapeutic strategies for the 
elderly.
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